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has no impact on local control when bone involvement or resection margins were positive, but if the resection was complete,
most authors recommend the use of these two treatment arms.
http://dx.doi.org/10.1016/j.rpor.2013.03.279
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Objective. To analyze the acute toxicities in rRT with curative intent in CCC.
Methods. Retrospective review of 21 patients reirradiated due to CCC with curative intent between May 2004 and December 2012.
All were treated by 3D technique with 6 MV photons. On 1st fractionation RT with 2Gy/day and rRT with 1.8Gy/day. Toxicity was
collected according to RTOG scale.
Results. Initial treatment was concomitant cisplatin-based chemoradiation in 9 patients, surgery plus adjuvant RT in 7, neoad-
juvant RTCT in 3 and exclusive RT in 2. In the second disease were 11 local recurrences objectiﬁed, 7 nodal recurrences and 3
seconds tumors. We chose concomitant RTCT with different chemotherapy regimens in 11 patients, surgery plus adjuvant RTCT
in 7 patients and surgery plus adjuvant RT in 3. The average time between the end of the ﬁrst irradiation and rRT was 24 months,
one case less than six months. The mean dose of the 1st RT was 67.7Gy and 64.3Gy in rRT. The PTV in the 1st irradiation was
256.8 cc and 119.3 cc of the rRT. The acute toxicities occur in higher incidence in the rRT. Radiodermatitis was presented in 25% in
the 1 st RT (grade I 25%, 50% Grade II, 25% Grade III) and 50% by rRT (grade II 37%, 63% Grade III). Odynophagia occurred in 31.3%
in the 1st RT (grade I 20%, 60% grade II, grade III 20%) and 43.8% in rRT (grade II 57.1%, 42.9% grade III). Mucositis was presented
in 37.5% in the 1st RT (grade I 33%, 33% grade II, grade III 33%) and 25% by rRT (grade I 25%, 50% grade II, 25 grade III %). Note that
it has made no toxic death by rRT. To date, the average follow-up is 15.4 months. Currently 7 patients are alive, free of disease 4.
Conclusions. We believe that the rRT in CCC is acceptably tolerated and should be considered as a therapeutic option in selected
cases.
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Reirradiation in head and neck cancer patients after recurrence or new primary tumors
A. Mut1, M. Chust1, L. Arribas1, J. Samper1, P. Santamaría1, V. Carrizo2, C. Pesudo1, J. Cruz3, J. Lavernia4,
J. Vendrell 5
1 Fundación Instituto Valenciano de Oncología, Oncología Radioterápica
2 Complejo Hospital General de Albacete, Oncología Radioterápica
3 Fundación Instituto Valenciano de Oncología, Anatomía Patológica
4 Fundación Instituto Valenciano de Oncología, OncologIa Médica
5 Fundación Instituto Valenciano de Oncología, Otorrinolaringología
Purpose. To analyze a retrospective review of the outcomes in patients who underwent re-irradiation (re-RT), after recurrent or
new primary head and neck cancer (HN) at our institution.
Methods and materials. 27 patients with HN cancer were treated with re-RT at our center, from April 2004 to November 2012,
consisting of 23 men and 4 women. Median age was 64 years. Tumor sites of recurrence or new primary included oral cavity
(n=7), larynx (n=5), hypopharynx (n=3), oropharynx (n=1), skull base (n=2), neck (n=5), paranasal sinuses (n=1), parotid (n=1),
skin (n=1) and esophagus (n=1). Median prior RT dose was 66Gy, and median re-RT dose was 59.7Gy. All patients, except one,
received chemotherapywith re-RT. IMRTwas used as re-RT technique in 17 cases (63%), and stereotactic body radiotherapy (SBRT)
in 5 (18.5%).
Results. At the present moment, 15 patients (55.5%) were alive; 10 of them, with no evidence of disease. The median follow-up was
of 17 months. Re-RT control and disease control rates were 63% and 48.1%, respectively. Mean survival since re-RT achieved 22.46
months, whereas mean local progression-free survival (LPFS) was 16.77. The probability of local control, one year after re-RT,
was 67%, and after 2 years, 54%. The most frequent acute toxicity was dermatitis (≥G2 in 40.7%). 3 patients (11.1%) presented
osteonecrosis requiring either hyperbaric oxygen ormedical treatment. Severe late toxicity, such as carotid blow-up,was reported
in one case. One patient died during re-RT and concurrent chemotherapy treatment due to sepsis.
Conclusions. Recurrence and/or appearance of new primary HN tumors lead to a variety of possible treatments, being re-RT a
feasible option that can obtain acceptable results, as demonstrated by our data, although late toxicity risks should be considered.
Therefore, patients who undergo re-RT must be carefully selected, in order to assure beneﬁt from re-RT.
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